000282542 001__ 282542
000282542 005__ 20260105130708.0
000282542 0247_ $$2pmid$$apmid:40817636
000282542 0247_ $$2doi$$a10.1002/bcp.70194
000282542 0247_ $$2ISSN$$a0306-5251
000282542 0247_ $$2ISSN$$a1365-2125
000282542 0247_ $$2pmc$$apmc:PMC12648363
000282542 037__ $$aDZNE-2025-01305
000282542 041__ $$aEnglish
000282542 082__ $$a610
000282542 1001_ $$00009-0002-1186-355X$$aLepenies, Laura K.$$b0
000282542 245__ $$aDeprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de
000282542 260__ $$aOxford$$bWiley-Blackwell$$c2025
000282542 3367_ $$2DRIVER$$aarticle
000282542 3367_ $$2DataCite$$aOutput Types/Journal article
000282542 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765543088_18547
000282542 3367_ $$2BibTeX$$aARTICLE
000282542 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282542 3367_ $$00$$2EndNote$$aJournal Article
000282542 520__ $$a Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline.The AgeWell.de study, a multi-centre, cluster-randomized controlled study, was conducted in 123 German general practices between June 2018 and January 2022. The study included a multicomponent intervention programme for patients at increased risk of dementia, delivered over a 2-year period. As part of the medication optimisation intervention, patient data and medication records were screened to identify medication risks and provide recommendations to general practitioners.In total, 808 patients with complete data were included in the present analysis (intervention group = 374, control group = 434). At baseline, 132 (16.8%) patients had at least one anticholinergic prescription. After 2 years, approximately one-third of these patients no longer received drugs with anticholinergic effects. There were no significant differences between the intervention and control groups, with 67.6% and 72.1%, respectively, continuing to take drugs with anticholinergic effects (P = 0.57). Patients reported anticholinergic symptoms more frequently when taking any medication (5.0% vs 33.8%), and even more so when taking drugs with anticholinergic effects (56.1%). Deprescribing of all drugs with anticholinergic effects was non-significantly higher in patients who reported at least one anticholinergic symptom compared to patients without any anticholinergic symptoms (58.6% vs 54.1%).The medication optimisation intervention did not entail significant differences in anticholinergic deprescribing between the groups.
000282542 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282542 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000282542 650_7 $$2Other$$aanticholinergic drugs
000282542 650_7 $$2Other$$adementia
000282542 650_7 $$2Other$$adeprescribing
000282542 650_7 $$2Other$$alifestyle intervention
000282542 650_7 $$2Other$$arandomized controlled study
000282542 650_7 $$2NLM Chemicals$$aCholinergic Antagonists
000282542 650_2 $$2MeSH$$aHumans
000282542 650_2 $$2MeSH$$aCholinergic Antagonists: adverse effects
000282542 650_2 $$2MeSH$$aCholinergic Antagonists: administration & dosage
000282542 650_2 $$2MeSH$$aMale
000282542 650_2 $$2MeSH$$aFemale
000282542 650_2 $$2MeSH$$aDementia: prevention & control
000282542 650_2 $$2MeSH$$aDementia: chemically induced
000282542 650_2 $$2MeSH$$aDementia: epidemiology
000282542 650_2 $$2MeSH$$aAged
000282542 650_2 $$2MeSH$$aDeprescriptions
000282542 650_2 $$2MeSH$$aAged, 80 and over
000282542 650_2 $$2MeSH$$aInappropriate Prescribing: prevention & control
000282542 650_2 $$2MeSH$$aGermany
000282542 650_2 $$2MeSH$$aCounseling: methods
000282542 650_2 $$2MeSH$$aGeneral Practice
000282542 650_2 $$2MeSH$$aCognitive Dysfunction: prevention & control
000282542 650_2 $$2MeSH$$aCognitive Dysfunction: chemically induced
000282542 650_2 $$2MeSH$$aRisk Factors
000282542 7001_ $$00000-0002-1215-634X$$aSeidling, Hanna M.$$b1
000282542 7001_ $$aPabst, Alexander$$b2
000282542 7001_ $$aLuppa, Melanie$$b3
000282542 7001_ $$aDöhring, Juliane$$b4
000282542 7001_ $$aWilliamson, Martin$$b5
000282542 7001_ $$aFrese, Thomas$$b6
000282542 7001_ $$aGensichen, Jochen$$b7
000282542 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b8$$udzne
000282542 7001_ $$aKaduszkiewicz, Hanna$$b9
000282542 7001_ $$aKönig, Hans-Helmut$$b10
000282542 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b11$$udzne
000282542 7001_ $$aWiese, Birgitt$$b12
000282542 7001_ $$aRiedel-Heller, Steffi G.$$b13
000282542 7001_ $$00000-0003-1217-5134$$aCzock, David$$b14
000282542 773__ $$0PERI:(DE-600)1498142-7$$a10.1002/bcp.70194$$gVol. 91, no. 12, p. 3489 - 3500$$n12$$p3489 - 3500$$tBritish journal of clinical pharmacology$$v91$$x0306-5251$$y2025
000282542 8564_ $$uhttps://pub.dzne.de/record/282542/files/DZNE-2025-01305.pdf$$yOpenAccess
000282542 8564_ $$uhttps://pub.dzne.de/record/282542/files/DZNE-2025-01305.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000282542 909CO $$ooai:pub.dzne.de:282542$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000282542 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000282542 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000282542 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282542 9141_ $$y2025
000282542 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000282542 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000282542 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-16$$wger
000282542 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CLIN PHARMACO : 2022$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000282542 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-16
000282542 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x0
000282542 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x1
000282542 980__ $$ajournal
000282542 980__ $$aVDB
000282542 980__ $$aI:(DE-2719)1510600
000282542 980__ $$aI:(DE-2719)1510800
000282542 980__ $$aUNRESTRICTED
000282542 9801_ $$aFullTexts